Survodutide

Overview

Survodutide is an investigational once-weekly peptide that activates both the glucagon receptor and the GLP-1 receptor; the glucagon component is intended to raise energy expenditure and act directly on the liver, while GLP-1 activity reduces appetite and supports glycemic control. In a published Phase 2 trial in metabolic dysfunction-associated steatohepatitis (MASH), it significantly improved liver histology versus placebo, and a separate Phase 2 obesity trial showed clinically meaningful weight loss. The evidence is encouraging but mid-stage: as of 2026 it is in Phase 3 development (for both MASH and obesity) and is NOT FDA-approved. Developed by Boehringer Ingelheim (with Zealand Pharma). It is a true peptide.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Metabolic dysfunction-associated steatohepatitis (MASH) / liver fibrosis (investigational; Phase 2 human data, not FDA-approved)
• Weight loss / obesity (investigational; Phase 2 human data)
• Type 2 diabetes glycemic control (investigational; earlier human data)

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Labs — ALT/AST and other liver enzymes if a clinician is monitoring liver effects
• Smart scale — weight and body-fat % trend
• InBody/DEXA — skeletal muscle mass vs. fat mass during weight loss
• Labs — HbA1c and fasting glucose for glycemic response
• Subjective — daily nausea, appetite, and GI tolerability check-ins

Sources & References

1. [1]A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (NEJM, 2024)
2. [2]Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a phase 2 dose-finding trial — The Lancet
3. [3]Survodutide (BI 456906): GLP1/GCGR agonist — Boehringer Ingelheim